Pharmaceutical and biopharmaceutical manufacturing relies on the timely and seamless orchestration of many steps to meet aggressive timelines and ensure operational efficiency. A fundamental element of the processing workflow that can impact schedules is the use of multi-ton quantities of bulk raw materials such as buffers, salts and stabilizing chemicals. These raw materials are typically prepared in a just-in-time manner to meet dynamic production needs and enable rapid changeovers.
A year after acquiring ADC Bio, Sterling Pharma is expanding its Deeside, UK facility to better serve the growing antibody-drug conjugate (ADC) market. Sterling entered the ADC space in April 2021 through the acquisition of ADC Bio. The deal brought with it a 6,500 square-meter site in Deeside, Wales housing ADC and bioconjugation development laboratories. A year on and Sterling is committing a further £1 million ($1.3 million) to the site, increasing laboratory space from 275 to 419 square meters,…